Rchr
J-GLOBAL ID：202101009231531972
Update date: May. 23, 2024
Tanimura Keiko
Tanimura Keiko | Tanimura Keiko
Affiliation and department：
Job title：
Trainee
Research field (1)：
Respiratory medicine
Research keywords (3)：
がん免疫療法
, がん分子標的治療
, 呼吸器内科学
Research theme for competitive and other funds (3)：
- 2022 - 2024 Elucidation and overcoming the drug tolerant mechanism in RET-altered cancer
- 2020 - 2022 Elucidation and overcoming the drug tolerant mechanism in ALK-rearranged lung cancer
- 2016 - 2019 Analysis of molecular factor to influence of immuno-checkpoint inhibitor in lung cancer treatment
Papers (49)：
-
Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Hiroyuki Fujii, Satomi Morita, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, et al. Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study. JTO clinical and research reports. 2024. 5. 3. 100644-100644
-
Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, et al. Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50. Frontiers in immunology. 2024. 15. 1348034-1348034
-
Akihiro Yoshimura, Takayuki Takeda, Nobutaka Kataoka, Keiko Tanimura, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Kentaro Nakanishi, Yuta Yamanaka, et al. Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study. Frontiers in oncology. 2024. 14. 1303543-1303543
-
Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, et al. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status. Targeted oncology. 2023
-
Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, et al. First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers. 2023. 15. 20
ｍore...
MISC (18)：
-
片山勇輝, 山田忠明, 田中理美, 藤井博之, 谷村恵子, 竹田隆之, 岡田あすか, 塩津伸介, 千原佑介, 平沼修, et al. 進行期肺腺がんの複合免疫療法におけるTTF-1発現の意義:多施設共同前向き観察研究. 日本肺癌学会学術集会号. 2022. 63rd (CD-ROM)
-
谷村 恵子, 山田 忠明, 森本 吉恵, 岩破 將博, 金子 美子, 内野 順治, 高山 浩一, 大村 亜矢香, 塩津 伸介, 片岡 伸貴, et al. 進行非小細胞肺がんの免疫チェックポイント阻害薬における血管新生阻害薬治療歴と治療効果の関連についての多施設共同後方視的検討. 肺癌. 2021. 61. 3. 241-242
-
谷村 恵子, 山田 忠明, 岡田 康太郎, 米田 和恵, 矢野 聖二, 内野 順治, 片山 量平, 高山 浩一. ALK融合遺伝子陽性肺がんのHER3活性を介したALK-TKI初期治療抵抗性の解明. 肺癌. 2020. 60. 6. 569-569
-
谷村 恵子, 米田 和恵, 矢野 聖二, 堀中 真野, 酒井 敏行, 片山 量平, 山田 忠明. ALK陽性肺がんにおいてHER3はALK阻害薬への治療抵抗性を克服するための治療標的となる. 日本癌学会総会記事. 2020. 79回. OE14-5
-
田宮 暢代, 瀬古 友利恵, 吉村 彰紘, 西岡 直哉, 中野 貴之, 大倉 直子, 山本 千恵, 谷村 恵子, 今林 達哉, 千原 祐介, et al. 切除可能肺癌合併COPDの周術期における長時間作用性β2刺激薬/長時間作用性抗コリン薬配合吸入剤効果の検討. 肺癌. 2019. 59. 6. 846-846
ｍore...
Education (2)：
- 2016 - 2020 Kyoto Prefectural University of Medicine Graduate School of Medical Science
- 2003 - 2009 Kyoto Prefectural University of Medicine
Professional career (1)：
Work history (2)：
- 2021/04 - 現在 Kyoto Prefectural University of Medicine Pulmonary Medicine Trainee
- 2020/04 - 2021/03 Kyoto Prefectural University of Medicine Pulmonary Medicine Researcher
Awards (1)：
- 2020 - 日本肺癌学会 優秀論文賞 非小細胞肺がんの免疫チェックポイント阻害薬における自己免疫関連有害事象と治療効果の関連についての検討
Return to Previous Page
